Heron Therapeutics (NASDAQ:HRTX) Upgraded to "Buy" at Wall Street Zen

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Friday.

Separately, Needham & Company LLC reissued a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a report on Friday, April 11th.

Heron Therapeutics Stock Performance

Heron Therapeutics stock traded up $0.02 during midday trading on Friday, hitting $2.12. 1,009,991 shares of the company were exchanged, compared to its average volume of 2,240,766. The business has a fifty day simple moving average of $2.01 and a two-hundred day simple moving average of $1.88. Heron Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The firm has a market capitalization of $323.44 million, a PE ratio of -11.78 and a beta of 1.15.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million for the quarter, compared to analysts' expectations of $37.08 million. As a group, equities analysts expect that Heron Therapeutics will post -0.13 earnings per share for the current year.

Hedge Funds Weigh In On Heron Therapeutics

A number of hedge funds have recently bought and sold shares of HRTX. Nicolet Advisory Services LLC purchased a new position in Heron Therapeutics during the fourth quarter valued at $25,000. RFP Financial Group LLC purchased a new position in Heron Therapeutics during the first quarter valued at $26,000. Argent Advisors Inc. purchased a new position in Heron Therapeutics during the fourth quarter valued at $31,000. Focus Partners Wealth purchased a new position in Heron Therapeutics during the fourth quarter valued at $31,000. Finally, Valeo Financial Advisors LLC lifted its holdings in Heron Therapeutics by 34.1% during the first quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 4,619 shares in the last quarter. Hedge funds and other institutional investors own 80.01% of the company's stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.